Breaking News Instant updates and real-time market news.

ATNX

Athenex

$14.56

-2.38 (-14.05%)

, MRK

Merck

$89.18

0.84 (0.95%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55

Society of Surgical Oncology to hold a symposium

San Antonio Breast Cancer Symposium 2019 will be held in San Antonio, TX on December 10-14.

ATNX

Athenex

$14.56

-2.38 (-14.05%)

MRK

Merck

$89.18

0.84 (0.95%)

ONCS

OncoSec

$2.00

-0.39 (-16.32%)

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ATNX Athenex
$14.56

-2.38 (-14.05%)

12/06/19
RHCO
12/06/19
INITIATION
Target $28
RHCO
Buy
Athenex initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Athenex with a Buy rating and $28 price target. The analyst notes that the company's "lead oral chemotherapy" platform could be a "better option" for some breast cancer patients. Karnauskas is also positive on the company's experienced large pharma management and claims that Athenex can improve older products with their "chemistry, formulation, and know-how". The analyst adds that her projections are "conservative" in modeling only 10% and 15% penetration into certain markets for oral docetaxel and irinotecan, with "full credit" adding about $92 per share to her price target.
11/19/19
RBCM
11/19/19
NO CHANGE
RBCM
Outperform
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
RBC Capital analyst Kennen MacKay noted that the San Antonio Breast Cancer Symposia, or SABCS, announced that Athenex's oraxol abstract was selected for the event's official press program and will remain under embargo until the morning of its presentation on December 13. He stated that SABCS "traditionally selects what they see as the most practice changing and sensational abstracts" for media embargo, calling this the "third SABCS win" for the company following a title change to reflect oraxol achieving a survival advantage and the inclusion of "major breast cancer KOL thought leader" Dr. Hope Rugo. MacKay keeps an Outperform rating on Athenex shares.
08/07/19
RBCM
08/07/19
NO CHANGE
Target $31
RBCM
Outperform
Athenex's Oraxol data 'near best-case,' says RBC Capital
Athenex announced results from the phase 3 trial of Oraxol in metastatic breast cancer patients that "approach a best case scenario," according to RBC Capital analyst Kennen MacKay, who views these data as demonstrating outstanding efficacy, durability, and safety/tolerability improvement. He models Oraxol achieving peak risk-unadjusted U.S. sales of $1B and global sales of $1.5B in metastatic breast cancer, noted MacKay, who expects the stock to trade to roughly $30 per share following the data. He keeps an Outperform rating and $31 price target on Athenex shares.
12/13/19
RBCM
12/13/19
NO CHANGE
RBCM
Outperform
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
RBC Capital analyst Kennen MacKay noted that SABCS released the previously press-embargoed abstract for Athenex's phase 3 Oraxol data, stating that the about 11 month median OS benefit with 50%+ ORR in metastatic breast cancer "surpasses our best case assumptions." Neuropathy has been a major focus at the meeting and he sees Oraxol "as a clear winner," though he expects Oraxol's overall safety profile will also be an investor focus in this afternoon's presentation given that rates of grade 3+ neutropenia and grade 3+ GI-toxicity were both numerically higher per the initial top-line press release. MacKay sees early trading volatility in shares of Athenex as a buying opportunity ahead of this afternoon's full data and discussion and keeps an Outperform rating on the stock.
MRK Merck
$89.18

0.84 (0.95%)

12/12/19
STFL
12/12/19
NO CHANGE
Target $17
STFL
Buy
Stifel says TherapeuticsMD's Annovera 'insulated' against generic NuvaRing
After Amneal Pharmaceuticals (AMRX) announced this morning that it has received approval from the FDA to market EluRyng, the first generic version of Merck's (MRK) NuvaRing Stifel analyst Annabel Samimy said the new contraceptive vaginal ring entrant may pose a threat to NuvaRing, but she believes TherapeuticsMD's (TXMD) competitor in the class, Annovera, is "insulated" by key product profile distinctions. Samimy points to Annovera's differentiated progesterone and long-acting system to support her view that Annovera successful early launch should shielded from disruption. She maintains a Buy rating and $17 price target on TherapeuticsMD shares.
12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.
ONCS OncoSec
$2.00

-0.39 (-16.32%)

02/01/19
PIPR
02/01/19
NO CHANGE
Target $3
PIPR
Overweight
Piper says OncoSec's TAVO resensitizing anti-PD-1 progressers 'impressive'
After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck's (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO's ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers "impressive." He reiterates an Overweight and $3 price target on OncoSec shares.
05/22/19
05/22/19
NO CHANGE

OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on OncoSec shares after the company's interim Phase II KEYNOTE-890 data for TAVO IL-12 plus Keytruda in ten evaluable TNBC, or triple-negative breast cancer, patients showed two partial responses and four patients with stable disease at three-months. The analyst noted that full results are expected in the second half of the year. Tenthoff reset his price target on share to $8 from $30 split adjusted "due to dilution from recent financing." The lower price target is "based on $104M enterprise value, down from $225M."
10/10/19
PIPR
10/10/19
NO CHANGE
Target $8
PIPR
Overweight
Piper keeps Overweight on OncoSec after China Grand investment
Piper Jaffray analyst Edward Tenthoff keeps an Overweight rating on shares of OncoSec Medical with an $8 price target after the company announced a $30M investment by China Grand Pharmaceutical. If concluded, the investment would increase OncoSec's pro forma cash to $63M with 22.6M shares outstanding, Tenthoff tells investors in a research note. Next the analyst expects Keynote-890 data on Tavo in triple negative breast cancer at the San Antonio Breast Cancer Symposium in December.

TODAY'S FREE FLY STORIES

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOLS

Evolus

$11.43

0.25 (2.24%)

10:19
01/17/20
01/17
10:19
01/17/20
10:19
Recommendations
Evolus analyst commentary  »

Evolus shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEL

Velocity Financial

$0.00

(0.00%)

10:18
01/17/20
01/17
10:18
01/17/20
10:18
Syndicate
Breaking Syndicate news story on Velocity Financial »

Velocity Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
01/17/20
01/17
10:17
01/17/20
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
01/17/20
01/17
10:16
01/17/20
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
U.S. JOLTS reported job openings dropped -561k to 6,800k in November »

U.S. JOLTS reported job…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

, GWB

Great Western

$34.30

-0.06 (-0.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

GWB

Great Western

$34.30

-0.06 (-0.17%)

TTEC

TTEC Holdings

$42.81

0.4 (0.94%)

BGNE

BeiGene

$169.94

2.055 (1.22%)

AMED

Amedisys

$181.47

0.28 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 28

    Jan

  • 04

    Feb

  • 27

    Feb

MS

Morgan Stanley

$56.87

0.42 (0.74%)

, TWTR

Twitter

$34.39

0.2 (0.58%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MS

Morgan Stanley

$56.87

0.42 (0.74%)

TWTR

Twitter

$34.39

0.2 (0.58%)

EBAY

eBay

$35.70

-0.21 (-0.58%)

CAKE

Cheesecake Factory

$39.21

-1.3 (-3.21%)

IBM

IBM

$137.21

-0.79 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 12

    Feb

WDC

Western Digital

$68.29

-0.33 (-0.48%)

, QCOM

Qualcomm

$93.76

1.99 (2.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

WDC

Western Digital

$68.29

-0.33 (-0.48%)

QCOM

Qualcomm

$93.76

1.99 (2.17%)

PINS

Pinterest

$23.36

0.4 (1.74%)

SNAP

Snap

$19.04

0.79 (4.33%)

YUM

Yum! Brands

$104.59

2.43 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

VEL

Velocity Financial

$0.00

(0.00%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Syndicate
Velocity Financial indicated to open at $13.70, IPO priced at $13.00 »

Velocity Financial (VEL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNV

Synovus

$39.86

0.24 (0.61%)

10:12
01/17/20
01/17
10:12
01/17/20
10:12
Conference/Events
Synovus management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Feb

  • 26

    Feb

PWFL

PowerFleet

$8.20

-0.04 (-0.49%)

10:10
01/17/20
01/17
10:10
01/17/20
10:10
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.